Direkt zum Inhalt
Merck
  • Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study.

Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study.

Epilepsia (2011-05-17)
Rima Nabbout, Cristiana Copioli, Mathilde Chipaux, Nicole Chemaly, Isabelle Desguerre, Olivier Dulac, Catherine Chiron
ZUSAMMENFASSUNG

We aimed to test the efficacy of ketogenic diet (KD) in patients with Dravet syndrome (DS) not satisfactorily controlled by antiepileptic drugs (AEDs). We included prospectively 15 DS patients aged >3 years with partial response to AEDs including stiripentol. All patients had a seizure diary and clinical examination with Conners and Achenbach scales before KD, at 1 month following onset and every 3 months thereafter. At 1 month, 10 patients (66%) had a decrease of seizure frequency ≥75%. Efficacy was maintained in eight responders at 3 and 6 months and in six responders at 9 months. Five patients (33%) remained on KD over 12 months, and one was seizure-free. In addition to efficacy on seizure frequency, KD was beneficial on behavior disturbances including hyperactivity. This effect was reported in all responders and in a few nonresponders. KD might have a double effect, on seizure control and on hyperactivity and behavior disturbances in patients with DS.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Stiripentol, ≥98% (HPLC)